投资要点2024 年经调整利润快速增长,BD 落地凸显创新实力,看好创新平台价值持续验证下估值提升机会。业绩:经调整净利润高增长公司2024 年业绩:集团收入66.35 亿元(YOY0.4%),归母净利润7.33 亿元(YOY2.6%),将投资收益和出售资产收益等调整后公司2024 年经调整归母净利润约人民币10.18 亿元(YOY41.6%)。多款创新药取得进展:2024 年新增2 款创新药恩立...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.